

**LINCOLN PHARMACEUTICALS LIMITED**  
REGD. OFFICE: "LINCOLN HOUSE", B/H. SATYAM COMPLEX, SCIENCE CITY ROAD, SOLA, AHMEDABAD-380 060.

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31.12.2013

(Rs. in Lacs)

PART - I PARTICULARS	CONSOLIDATED				STANDALONE					
	QUARTER ENDED 31.12.2013 (Un-Audited)	30.09.2013 (Un-Audited)	31.12.2012 (Un-Audited)	31.12.2013 (Un-Audited)	QUARTER ENDED 31.12.2013 (Un-Audited)	30.09.2013 (Un-Audited)	31.12.2012 (Un-Audited)	31.12.2013 (Un-Audited)	YEAR ENDED 31.03.2013 (Audited)	YEAR ENDED 31.03.2013 (Audited)
1 Income from operations	5199.40	5434.95	5109.95	14429.73	5116.69	5432.78	4891.38	14282.07	13230.41	19092.05
(a) Net Sales/Income from operation (Net of excise duty)	95.34	120.87	74.89	421.30	668.65	119.86	76.88	381.83	128.82	468.62
(b) Other operating income	5294.74	5555.62	5184.84	14851.03	5188.04	5552.64	4988.26	14673.90	13359.23	19561.67
2 Expenses										
(a) Cost of materials consumed	1071.58	1156.56	1163.84	3145.84	897.29	1080.27	609.41	2577.85	2762.81	3416.75
(b) Purchases of stock-in-trade	2552.48	2537.71	2778.56	6485.65	2778.56	2740.05	2778.56	7311.15	5890.07	9211.46
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-120.34	-135.71	-122.27	-352.31	-111.90	-94.04	-94.04	-211.15	-211.09	-117.69
(d) Employee benefits expense	485.44	449.45	500.70	1423.95	409.35	385.52	458.81	1213.13	1222.70	1587.23
(e) Depreciation and amortisation expense	91.47	87.84	61.85	264.77	59.36	55.85	53.05	170.85	155.64	207.94
(f) Other expenses	605.53	1017.54	930.34	2519.80	3291.06	934.19	852.79	2202.79	2409.52	3162.10
Total expenses	4891.96	5113.09	4931.16	13387.84	4955.73	5101.84	4678.23	13204.62	12229.74	17713.17
3 Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	602.78	442.53	253.68	1463.49	642.31	450.80	280.03	1469.28	1129.49	1848.50
4 Other income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5 Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)	602.78	442.53	253.68	1463.49	642.31	450.80	280.03	1469.28	1129.49	1848.50
6 Finance costs	198.82	48.24	135.98	392.29	172.23	46.55	110.31	311.90	327.60	715.91
7 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	403.96	394.29	117.70	1071.20	470.08	404.25	179.72	1157.38	801.89	1132.59
8 Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9 Profit/(Loss) from ordinary activities before tax (7+8)	403.96	394.29	117.70	1071.20	470.08	404.25	179.72	1157.38	801.89	1132.59
10 Tax expense	108.30	58.88	5.58	130.09	87.08	82.41	-17.68	72.50	138.20	151.32
11 Net Profit/(Loss) from ordinary activities after tax (9-10)	295.66	335.41	122.28	941.11	383.00	321.84	197.41	1084.88	663.69	981.27
12 Extraordinary items (Net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13 Net Profit/(Loss) for the period (11+12)	295.66	335.41	122.28	941.11	383.00	321.84	197.41	1084.88	663.69	981.27
14 Share of profit/(loss) of associates*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
15 Minority interest*	-32.43	-6.14	-28.18	-54.83	-12.80	-6.37	-12.80	0.00	0.00	0.00
16 Net Profit/(Loss) after taxes, minority interest and shares of profit/(loss) of associates (13-14+15)*	330.09	341.55	149.46	995.74	383.00	351.84	197.41	1084.88	663.69	981.27
17 Paid-up equity share capital of face value Rs.10/- each	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08
18 Reserve excluding Revaluation Reserves as per balance sheet of previous a/c. year	2.02	2.09	0.92	6.10	2.35	2.16	1.21	6.65	4.07	6.02
19 (a) Basic and diluted EPS before Extraordinary items (a, 10/- each) and Prior period Adjustment (Not Annualised)	2.02	2.09	0.92	6.10	2.35	2.16	1.21	6.65	4.07	6.02
(b) Basic and diluted EPS after Extraordinary items (a, 10/- each) and Prior period Adjustment (Not Annualised)										
<b>PART - II</b>										
<b>A. PARTICULARS OF SHAREHOLDING</b>										
1 Public Shareholding:										
-Number of shares	10971449	10971449	11737496	10971449	10971449	10971449	11737496	10971449	11737496	10974068
-Percentage of Shareholding	67.26	67.26	71.96	67.26	67.26	67.26	71.96	67.26	71.96	67.28
2 Promoters and Promoter group Shareholding:										
a) Pledged/Encumbered										
-Number of shares	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
-Percentage of Shareholding (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
b) Non-encumbered										
-Number of shares	5339351	5339351	4573304	5339351	5339351	5339351	4573304	5339351	4573304	5336712
-Percentage of Shareholding (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
-Percentage of Shareholding (as a % of the total share capital of the Company)	32.74	32.74	28.04	32.74	32.74	32.74	28.04	32.74	28.04	32.72
<b>Quarter ended on 31.12.2013</b>										
<b>B. INVESTOR COMPLAINTS</b>										
Pending at the beginning of the quarter	NIL									
Received during the quarter	2									
Disposed of during the quarter	2									
Remaining unresolved at the end of the quarter	NIL									
<b>NOTES:-</b>										
1. The above results were approved by the Board of Directors at its meeting held on 13.02.2014.										
2. Previous year figures are regrouped/reclassified to conform to the current year's presentation.										
3. Since the revenue from different segments is less than 10% of total revenue, segment wise results are not given.										
4. Statutory Auditors has carried out limited review for the quarterly result for quarter ended 31.12.2013.										
5. Consolidated results includes results of two subsidiary Company-1, Zullif Healthcare Ltd.(WOS) and 2.Lincoln Parenteral Ltd.(Subsidiary)										



*(Signature)*  
**(Mahendrag. Patel)**  
Managing Director

Place : Ahmedabad.  
Date : 13.02.2014.